載入中
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
前收盤價
US$7.41
+US$0.22 · +3.06%
盤中時間採用ET。市場資料可能有所延遲。
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
日內區間
目前US$7.41
52週區間
目前US$7.41
盤中時間採用ET。市場資料可能有所延遲。
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
日內區間
目前US$7.41
52週區間
目前US$7.41
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 22.8萬 USD | 22.9萬 USD | — | — | — |
| 毛利 | −22.8萬 USD | −22.9萬 USD | — | — | — |
| 研究與開發 | 2296.4萬 USD | 2281.7萬 USD | 1581.4萬 USD | 3007.8萬 USD | 2396.6萬 USD |
| 銷售、一般及管理費用 | 3186.8萬 USD | 1625.2萬 USD | 1143.6萬 USD | 1072.2萬 USD | 912.8萬 USD |
| 營業費用 | 5465.2萬 USD | 3884萬 USD | 2725萬 USD | 4080萬 USD | 3309.4萬 USD |
| 利息收入 | 149.5萬 USD | 235.6萬 USD | 82.5萬 USD | 19.9萬 USD | 1.7萬 USD |
| 利息支出 | 81.9萬 USD | 218萬 USD | 285.3萬 USD | 178.9萬 USD | — |
| 折舊和攤銷 | 22.8萬 USD | 22.9萬 USD | 22.8萬 USD | 23.6萬 USD | 25萬 USD |
| 營業利益 | −5488萬 USD | −3906.9萬 USD | −2725萬 USD | −4080萬 USD | −3309.4萬 USD |
| 淨利 | −5464.8萬 USD | −3982.7萬 USD | −2981.5萬 USD | −4235萬 USD | −3315.2萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$14.80
上漲空間 99.73%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2020年7月31日 | 1:20 | — | — |
股票分割 | 2018年5月24日 | 1:10 | — | — |
股票分割 | 2017年8月3日 | 1:11 | — | — |
股票分割 | 2008年8月21日 | 1:18 | — | — |
已生效 2020年7月31日
1:20
已生效 2018年5月24日
1:10
已生效 2017年8月3日
1:11
已生效 2008年8月21日
1:18
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2468.04萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1527.1萬0.15%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1486.81萬0.02%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF768.77萬0.01%954億 USD0.05%US$235+0.80%
Simplify Propel Opportunities ETFSURI690.69萬9.08%7606.44萬 USD2.82%US$17.06-0.14%
iShares Russell 2000 Growth ETFIWO509.99萬0.04%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO354.81萬0.02%180億 USD0.06%US$112.66+0.50%
Fidelity Enhanced Small Cap ETFFESM225.39萬0.03%64.1億 USD0.28%US$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFSimplify Propel Opportunities ETFSURIiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
